Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;38:569-575
doi: 10.1161/hy09t1.095393
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bezerra, S. M.M.S.
Right arrow Articles by Michelini, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bezerra, S. M.M.S.
Right arrow Articles by Michelini, L. C.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow ACE/Angiotension receptors
Right arrow Other hypertension
Right arrow Hypertension - basic studies
Right arrow Autonomic, reflex, and neurohumoral control of circulation

(Hypertension. 2001;38:569.)
© 2001 American Heart Association, Inc.


Neurogenic Factors

Chronic AT1 Receptor Blockade Alters Autonomic Balance and Sympathetic Responses in Hypertension

Simone M.M.S. Bezerra; Claudia M. dos Santos; Edson D. Moreira; Eduardo M. Krieger; Lisete C. Michelini

Department of Physiology and Biophysics, ICB (S.M.M.S.B., C.M.d.S., L.C.M.) and Heart Institute (E.D.M., E.M.K.), University of São Paulo, São Paulo, SP, Brazil.

Correspondence to Lisete C. Michelini, PhD, Department of Physiology and Biophysics, Institute of Biomedical Sciences, USP, Av. Prof. Lineu Prestes, 1524, 05508-900 Sao Paulo, SP, Brazil. E-mail michelin{at}usp.br

Abstract

Abstract— In the coarctation hypertension model, we have shown that chronic treatment with losartan causes both normalization of impaired reflex control of heart rate and partial correction of the depressed aortic nerve activity/pressure relationship, even with the persistence of hypertension. In the present study, we analyzed the effects of angiotensin II blockade on the efferent pathways of coarcted and sham-operated groups treated chronically with vehicle or losartan (10 mg/kg per day PO). Hypertension was induced by subdiaphragmatic aortic coarctation, and the treatments lasted 9 days (4 control and 5 experimental days). On day 5, autoregressive power spectral analysis was performed on heart rate recordings made in conscious rats. Other groups were used for sympathetic splanchnic nerve activity recordings made simultaneously with pressure (anesthetized rats) at basal condition and during loading/unloading of baroreceptors. Losartan treatment induced a significant reduction in basal pressure but did not interfere with the development of hypertension (similar pressure increases of 24% and 28% over control values in losartan and vehicle groups, respectively). In vehicle-treated rats, establishment of hypertension was accompanied by a marked change in power spectral density from high- (1.19±0.06 Hz, 33±6%) to low-frequency components (0,42±0.03 Hz, 54±6%), with increased low-frequency–to–high-frequency ratio. When compared with sham-operated vehicle-treated rats, there was also increase in the gain of sympathetic activity/pressure relationship, with displacement of lower plateau toward high levels of sympathetic activity. No changes in the power spectral density and sympathetic activity/pressure relationship were observed when hypertension developed in the presence of chronic angiotensin type 1 (AT1) receptor blockade. The data suggest that angiotensin II, activated during the establishment of coarctation hypertension, acts via AT1 receptors to alter sympathovagal balance, facilitating the sympathetic outflow to heart and peripheral circulation during baroreceptors unloading. Data also indicate that the observed effects are not conditioned by preexisting pressure levels.


Key Words: receptors, angiotensin II • losartan • blood pressure • heart rate • hypertension, experimental • rats

It is well known that the renin-angiotensin system (RAS) is involved in cardiovascular regulation and in the development/maintenance of hypertension.15 The presence of an endogenous RAS in brain areas involved in cardiovascular regulation has been confirmed by several techniques.3,6,7 Stimulation of high affinity angiotensin (Ang) II receptors8 leads to a set of coordinated autonomic and endocrine responses yielding to blood pressure increase and hypertension.1,2,5,8,9

Blockade of RAS usually reverses the angiotensin-induced effects simultaneously with a significant pressure reduction. It is not well established if the various autonomic/endocrine changes observed in hypertension were caused only by the direct effect of Ang II, by the concomitant blood pressure increase, or by a combination of both. In this regard, coarctation hypertension (CH) caused by subdiaphragmatic aortic constriction is an advantageous model of hypertension. In CH, pressure increase is determined mainly by the elevated resistance interposed to the circulation (mechanical factor10,11), in such a way that converting-enzyme inhibition and angiotensin type 1 (AT1) receptor blockade cause small reductions but do not impair the development and magnitude of hypertension.12,13

In CH rats, we showed that increased baseline heart rate (HR) and the impaired baroreceptor reflex control of HR were Ang II–specific effects, not conditioned by the hypertensive levels, because chronic AT1 receptor blockade normalized both, without interfering with the pressure load.12 We showed also that Ang II, activated during CH, depressed the afferent signaling of aortic baroreceptors.13 However, aortic nerve gain was only partially corrected by chronic AT1 receptor blockade,13 suggesting that complete normalization of baroreflex control of the heart should involve other effects.

Not knowing if the characteristic hypertension-induced changes in the sympathetic tone to the periphery and its reflex control are caused by Ang II itself and/or by the concomitant pressure elevation, the objectives of the present study were (1) to determine in CH and normotensive control rats the effects of chronic blockade of AT1–Ang II receptors on both basal sympathetic tone and sympathetic nerve activity during loading/unloading of baroreceptors and (2) to determine the autonomic balance to the heart in CH and normotensive rats treated chronically with vehicle or losartan.

Methods

Male Wistar rats (ICB, University of San Paulo), aged 3 to 4 months and weighing 200 to 300 g, were used. During the experimental period, the rats were housed in individual cages on a 12-hour/12-hour light/dark schedule and allowed free access to standard laboratory chow and water. All surgical procedures and protocols used were in accordance with Ethical Principles in Animal Research (Brazilian College of Animal Experimentation) and were approved by University of Sao Paulo Ethical Committee for Animal Research. Rats were treated orally for 9 days with vehicle (VEH) (distilled water, 1 mL · kg-1 · d-1) or losartan (LOS) (10 mg · kg-1 · d-1). After a control period (4-day treatment), half of the rats in VEH and LOS groups were submitted to CH, whereas sham-operated rats (SH), the other half, served as controls.

CH, which induces hypertension of the upper part of systemic circulation, was produced by partial subdiaphragmatic aortic constriction, by a technique described previously.14 Briefly, under ether anesthesia, the rats were submitted to median laparotomy and isolation of the abdominal aorta just below the diaphragm and near the exit of the superior mesenteric artery. A cotton thread was used to constrict the aorta, the extent of narrowing being limited by a hypodermic needle (0.7 to 0.9 mm OD), according to the rat’s body weight. The needle was removed, and the abdomen was sutured. SH rats were submitted to the same surgical procedures, except for the narrowing of the abdominal aorta. All rats received 60 000 IU of penicillin (Pentabiótico Veterinário, Fontoura-Wyeth).

Pressure was measured by a tail-cuff technique (Programmed Sphygmomanometer, PE-300, Narco Bio-Systems) 7 to 10 days before starting the treatments and on day 4 of LOS or VEH therapy, immediately before CH or SH surgery. Arterial pressure (AP) was also measured directly (P23Db transducer, Gould-Statham) on day 5 of CH or SH. The right common carotid artery was cannulated on day 4 to allow complete recovery from ether anesthesia. The rat was connected to the recording system (General Purpose Amplifier, Stemtech Inc), and 20 to 30 minutes was allowed for the stabilization of the cardiovascular parameters. Basal AP and HR were recorded continuously for 60 to 70 minutes in conscious unrestrained rats (computer, sampled at 1000 Hz/channel) and stored on a disk for offline analysis. Systolic and diastolic pressure and HR values were acquired on a computer and subjected to analog-to-digital conversion (Codas-Windaq, DI-200).

Data analysis was performed in beat-to-beat time series of raw data. Data series were inspected visually on the computer screen to guarantee the accuracy of the automatic detection; segments with artifacts were systematically discharged. Mean values and standard deviation of the mean of HR series were calculated as an index of variability of these parameters on the time domain. The spectral density of the various frequency components of HR (frequency domain) was calculated by the autoregressive model (AR, model 12). The principles of the software for data acquisition and analysis have been described previously.15,16 AR power spectral analysis was made in short-term recording sequences (series of 512 and 1024 consecutive cardiac cycles) that allow for the detection of the central frequency and distribution of power of 2 main spectral components: low (LF) (0.25 to 0.75 Hz) and high frequency (HF) (0.75 to 3.00 Hz). AR analysis was repeated several times in stationary series (6 to 12) in the 60 to 70 minutes of continuous recording and the average central frequency (Hz) and power spectral density (in beats · min-2 · Hz and mm Hg2/Hz, or percentage of normalized units) used as rat individual values.

Other SHVEH, CHVEH, SHLOS, and CHLOS groups were used to record sympathetic nerve activity on experimental day 5. After measurement of AP in the conscious state, rats were intravenously anesthetized with a mixture of {alpha}-chloralose (50 mg/kg) and urethane (500 mg/kg), had the right jugular vein cannulated, and were prepared for recording splanchnic sympathetic nerve activity (SSNA). The procedure used to record whole nerve SSNA was similar to that used in previous studies.17,18 Upper left lateral laparotomy allowed for isolation of the left splanchnic nerve, which was placed on bipolar platinum electrodes; a third electrode, fixed in the muscle, served as reference. Whole SSNA was filtered (band pass of 100 to 3000 Hz), amplified (Differential Amplifier, 502A, Tektronix), full-wave rectified, and integrated (time constant of 3.9 milliseconds). The integrator output provides the nerve activity for each cardiac cycle (mV/cycle), continuously monitored on an oscilloscope (5115 Storage, Tektronix). SSNA was acquired online (computer, 3000 Hz sampling) with AP, subjected to analog-to-digital conversion (Codas), and stored. Because of great individual variability and multifiber preparation, SSNA was normalized and expressed as %/cardiac cycle. The experimental protocol consisted of measurements of SSNA/MAP relationship at basal condition (control, at least 20-minute record) and during MAP changes induced by intravenous infusions (100 µg/mL, 1 to 4 mL/h) and/or bolus injections (1 to 3 µg/kg) of phenylephrine and sodium nitroprusside. The data presented are the average of 2 to 3 consistent measurements made during each experimental situation for each rat. To represent SSNA responses during MAP changes the efferent discharge (%/cycle) was normalized, with the control SSNA value of 100%. Pressure-induced changes of SSNA were analyzed through logistic equations adjusted to data points19: Down



where P1 is the lower SSNA plateau; P2, SSNA range, P3, curvature coefficient (which is independent of range); and P4, MAP50 (ie, the MAP at half of SSNA range). The upper plateau is determined as P1+P2, and the average gain (G) or slope of the curve between the 2 inflection points is given by G=[(-P2xP3)/4].

Results are presented as mean±SEM. For all parameters, differences between groups (CH and SH) and treatments (LOS and VEH) were analyzed by 2-way ANOVA, followed by Student-Newman-Keuls multiple comparison test. Differences were considered significant at P<0.05.

Results

Blood Pressure Changes
In the control period, the 4-day LOS treatment caused a significant reduction of tail pressure (93±4 versus 112±3 mm Hg in the VEH-treated rats, Table). On experimental day 5, direct measurements of pressure in the conscious state confirmed that both CHVEH and CHLOS groups were hypertensive (154±3 and 133±3 mm Hg) (Table) compared with respective controls (120±3 and 107±4 mm Hg in SHVEH and SHLOS, corresponding to equal pressure loads of 28% and 24%, respectively).


View this table:
[in this window]
[in a new window]
 
Table 1. Values of MAP, HR, LF, and HF Components of HR Variability and SSNA in VEH- and LOS-Treated Groups Submitted to CH or SH

HR Variability
Figure 1 illustrates the power spectral density of HR variability in 4 rats representative of the 4 groups. For SHVEH and SHLOS, the dominant frequency (with a higher fractional power) was found in the HF range (0.75 to 3.00 Hz). In CHVEH, but not in CHLOS, the dominant frequency moved to the LF range (0.25 to 0.75 Hz). Group means showed that baseline HR variability was characterized by 2 major spectral components at LF ({approx}0.4 Hz) and HF ({approx}1.2 Hz), with similar central frequencies among groups (Table 1). However, the fractional power differed markedly between groups: whereas in the SH groups HF predominates (33% to 35% of total power spectrum) over LF (smaller fractional power, in the range of 16% to 19%), in CHVEH rats there was a marked predominance of LF over HF (54±6% versus 14±1%, respectively) (Table), determining a marked increase in LF/HF ratio (from 0.90±0.42 to 4.66±1.12). On the other hand, the establishment of CH in LOS-treated rats did not change the HF or LF component and the LF/HF ratio (0.30±0.04 versus 0.46±0.10). Therefore, both LF and LF/HF ratio were significantly smaller in CHLOS versus CHVEH (Table).



View larger version (51K):
[in this window]
[in a new window]
 
Figure 1. Individual spectral components obtained from spontaneous heart rate variability in 4 conscious unrestrained rats representative of the 4 groups. Numbered lines indicate the different frequencies automatically determined by the program, whereas vertical dashed lines represent the limits of the LF component (0.25 to 0.75 Hz). In each spectrum, the predominant frequency was indicated by the dashed area.

Splanchnic Sympathetic Nerve Responses
At the conscious state, MAP of SHVEH, CHVEH, SHLOS, and CHLOS groups used for SSNA experiments were 111±2, 151±9, 104±2, and 128±5 mm Hg, respectively. Anesthesia did not change significantly MAP levels (values on the Table). At the control period, basal integrated SSNA (mV/cardiac cycle) (Table) was similar for all groups, corresponding to 29±4, 28±3, 28±5, and 30±2%/cycle in SHVEH, CHVEH, SHLOS, and CHLOS, respectively. Normalized basal SSNA (15-minute recording period) showed large variability but a negative relationship with spontaneous fluctuations of MAP. The slope of the regression lines were not different among groups, although sensitivity was 61% and 53% smaller in CHVEH and CHLOS versus respective controls (Table).

Figure 2 illustrates groups average sigmoidal logistic equations adjusted to SSNA responses during pressure changes, and the Tableshows the equations parameters for the 4 groups of rats. In VEH- and LOS-treated groups, establishment of hypertension caused a right-hand displacement of normalized curves toward higher MAP levels (both control MAP and MAP50 were increased) (Table). The slope of the curve (-10.36±1.05% · cycle-1 · mm Hg-1) and the lower plateau (45±5%/mm Hg) were only increased in CHVEH group (versus SHVEH group) (Figure 2). These effects were not present when hypertension developed in the presence of chronic AT1 receptor blockade. Because in the CH model of hypertension the narrowing of the aorta was not exactly the same in all animals (the extent of narrowing was based on body weight, an approximate index), hypertensive levels attained showed a continuous distribution with 2 subgroups exhibiting higher (153±3 mm Hg) and lower control MAP levels (123±3 mm Hg, a value similar to that of CHLOS group). The comparison of normalized SSNA/MAP curves in the CHVEH subgroups (Figure 2, lower panel) corroborates the observation that reflex gain and lower plateau displacement were not conditioned by the existing pressure level, because they were similarly increased in the higher (-9.49±1.27% · cycle-1 · mm Hg-1 and 45±6%/cycle, n=7) as well as in the lower MAP subgroups (-11.60±1.79% · cycle-1 · mm Hg-1 and 46±9%/cycle, n=6, respectively). Figure 2 also discriminates between the different effects of chronic LOS treatment on SSNA: (1) the pressure-lowering effect demonstrated by the displacement of the SHLOS and CHLOS curves to the left, according to the reduction in the respective control MAP, and (2) the restoration of efferent gain and normalization of the lower plateau during establishment of CH. On the other hand, LOS did not change SSNA/MAP relationship in SH rats.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 2. Upper panels, Comparison of normalized SSNA/MAP relationships in CH and SH anesthetized rats treated chronically with VEH or LOS. Lower panel, CHVEH group was represented as 2 subgroups, showing lower and higher MAP levels. P<0.05 vs SHVEH: *for gain; #for lower plateau comparisons.

Discussion

The present new set of data demonstrates that Ang II, activated by CH, acts on AT1 receptors to cause both marked increase in basal sympathetic tone to the heart and facilitation of SSNA responses during pressure challenges. The complete normalization of these responses with chronic AT1 receptor blockade, in the presence of similar pressure load, indicates the observed effects are not dependent of the pressure load.

Several studies have linked Ang II with altered cardiovascular functions in different models of hypertension.2023 On day 5 of CH, previous studies from our laboratory have shown overactivation of the RAS and increased baseline HR,11 depression of both reflex bradycardia and tachycardia,11,12 and increased variability of aortic nerve activity associated with reduction in the gain of afferent discharge/pressure relationship.13,24 In this model we also showed that chronic treatment with losartan caused complete normalization of both baseline HR and baroreceptor reflex control of heart rate12 but only a partial correction of aortic nerve activity/pressure relationship.13 What we show in the present study is that part of the depression of baroreflex control could be attributed to the effects of Ang II on efferent pathways, by changing the sympathovagal balance to the heart, by reducing peripheral sympathetic inhibition during pressure increases, and by facilitating sympathetic outflow during pressure decreases. It is interesting to note that in the CH model of hypertension, as showed before in the spontaneous hypertension,22 Ang II has an important role in influencing both baroreceptor reflex sensitivity and sympathetic outflow.

Several pieces of experimental evidence show that elevated Ang II levels are associated with increased sympathetic activity.4,21,22,25 Although the interaction between Ang II and peripheral sympathetic activity in hypertensive individuals has been extensively investigated, there are some controversies: increased,2,2629 decreased,2,29 or unchanged2,28,30 sympathetic activity has been described. Other works point out that increased sympathetic activity was not constant but transiently elevated at early hypertensive stages.31 Apart of the transient characteristic, the discrepant findings are certainly owing to the available methods to measure sympathetic activity (magnitude of pressure fall after sympathetic blockade, measurements of plasma norepinephrine release and turnover, direct neuronal recordings). Most of these techniques allow the determination of an indirect index of sympathetic activity, whereas sympathetic nerve traffic recording can measure it directly, but only in a specific region of anesthetized animals. Actually, our recordings of SSNA in anesthetized rats showed similar basal values in all groups, although the pressure-induced SSNA response was increased by CH and normalized by LOS. On the other hand, our results with power spectral analysis on spontaneous fluctuations of HR (and MAP) clearly showed the predominance of LF over HF components, indicative of an increased sympathetic tone32 after the establishment of hypertension in VEH-treated rats. It is possible to reconcile these apparently discrepant experimental findings in CHVEH rats. Similar basal SSNA (total discharge in mV/cardiac cycle) is a good index for the presence of baroreceptors resetting to hypertensive levels and permits the normalization of sympathetic inhibition in the chronic phase of CH, besides the maintenance of high pressure.17,18,33 On the other hand, the predominance of LF component indicates that the sympathetic inhibition in the CHVEH was not exactly similar but smaller than that of other groups, besides the similar total neural efferent activity. Actually, it is well documented in hypertension that in the presence of baroreceptors resetting, both baroreceptor reflex control of HR and total peripheral resistance were significantly depressed (smaller gain11,21,24,30). This could facilitate an increase in the sympathetic tone, as we show in the CHVEH group. The new observation was possible because of employment of the spectral analysis on spontaneous HR and MAP variability, a very sensitive method to distinguish even mild changes, not detected by the conventional methods.15,34

Power spectral analysis also revealed that not only the LF was favored, but the HF component was markedly reduced in CHVEH, thus contributing to alter sympathovagal balance to the heart. LF/HF ratio, used as an index of sympathovagal balance,15,32 showed that establishment of hypertension was accompanied by a huge change in the autonomic control of the heart from a vagal predominance to an intense sympathetic activity. This change may explain the marked depression of both reflex bradycardia (less efficient inhibition of sympathetic plus smaller response of the already depressed vagal tone) and reflex tachycardia (small range for further sympathetic increase) we observed previously in the chronic phase of CH.11 Our results with direct SSNA recordings also showed increased peripheral sympathetic outflow during loading/unloading of baroreceptors in the CHVEH. The significant displacement of lower plateau to high SSNA levels revealed a deficient withdrawal of sympathetic during transient pressure increases, which is consistent with reduced gain of sympathetic response described earlier in the chronic phase of hypertension.30 On the other hand, the larger gain of SSNA/MAP relationship was consistent with a potentiation of sympathetic response during transient pressure decreases. Ang II–induced depression of vagal afferents25,35 and attenuation of sympathetic vasoconstrictor responses to sympathetic nerve stimulation, hypothalamic simulation and intravenous norepinephrine injections in SHR chronically treated with captopril22 have been described previously.

Interestingly, the development of hypertension in the presence of chronic LOS treatment completely blocked all the observed effects, thus abolishing evidence of sympathetic overactivity. These results clearly indicated that Ang II triggers the sympathetic tone to the heart and splanchnic bed, via activation of AT1 receptors. Both AT1 and AT2 receptors subtypes have been mapped in the central nervous system of rats, but most of the functional Ang II effects are mediated by the G protein–coupled AT1 receptor.8,36 In addition, brain structures involved in cardiovascular control such the nucleus tractus solitarii, dorsal motor nucleus of the vagus, hypothalamic nuclei, and circumventricular organs have been shown to contain AT1–Ang II receptors exclusively.36 We showed before that Ang II has important effect on baroreflex control by altering aortic baroreceptor discharge,13 by acting in the nucleus tractus solitarii,37 and by changing sympathetic outflow (present results). Apart of these results and the central distribution of AT1 receptors,36 we still do not have experimental evidence on which areas are actually involved in the mediation of Ang II effects on sympathetic outflow during the establishment of CH.

It should be stressed that all the observed responses are due to the modulatory effect of Ang II and not to simultaneous pressure changes. Independent of LOS-induced MAP decreases (-17% by tail pressure, -11% and -12% in the conscious and anesthetized SH rats, respectively) (Table), establishment of CH caused similar pressure loads in VEH- or LOS-treated groups (+28% and +24%, respectively). In addition, the significant differences of lower plateau and SSNA/MAP gain between CHLOS and CHVEH low-pressure subgroup (presenting the same absolute MAP levels) clearly showed that the observed effects are not dependent on maintained pressure levels. Dissociation between pressure levels/plasma renin activity23 and between plasma renin activity/lower brain stem angiotensinogen mRNA levels38 has been demonstrated in rats made hypertensive by ligation of the aorta between the renal arteries. In accordance, we have previously shown that the modulatory effect of central Ang II on baroreceptor reflex control of heart rate was not dependent of the pressure level. Subpressor doses of Ang II administered into the nucleus tractus solitarii of normotensive rats depressed the reflex bradycardia37 and CH rats treated chronically with LOS showed normalization of reflex responses and aortic nerve activity even in the persistence of hypertension.12,13

Collister et al38 reported that chronic treatment with LOS was able to lower pressure of normotensive rats on normal-sodium diet. Accordingly, a similar daily dose of LOS caused a reduction of pressure levels in SH as CH groups, with similar magnitude and maintained throughout the experiment. The LOS-induced reduction in MAP emphasizes the importance of endogenous Ang II levels in the maintenance of basal vasoconstriction and in the determination of basal pressure in both groups. In the CH groups treated or not treated with LOS, the huge constriction of the upper abdominal aorta, imposing a large resistance to blood circulation (mechanical factor10) determined a similar increase in MAP, showing that the mechanical factor was not altered by LOS treatment. Another finding of the present study is that chronic AT1 receptor blockade did not change the sympathovagal balance and SSNA/MAP relationship in normotensive groups. Accordingly, LOS has been shown to not alter the basal firing pattern of Ang II–sensitive neurons in the medial nucleus tractus solitarii but only to reverse the increased firing and to block the excitation induced by Ang II administration.39

In summary, our data show that Ang II, activated by CH, has multiple effects on the efferent pathways. It acts on AT1 receptors to change sympathovagal balance, producing a marked increase in sympathetic outflow while inhibiting vagal outflow to the heart, to cause a deficient pressure-induced sympathetic withdrawal and to increase sympathetic tone to splanchnic circulation during unloading of baroreceptors. Chronic AT1 receptor blockade, not changing the pressure load but normalizing sympathovagal balance and sympathetic tone to the periphery, indicates that these effects are not conditioned by the pressure levels.

Acknowledgments

Supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 95/3738-0), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, 465209/00-9), Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, fellowship to S.M.M.S.B.), and Merck Sharp & Dohme (Educational Grant)

Received March 28, 2001; first decision May 30, 2001; accepted June 28, 2001.

References

1. Ferrario CM, Ueno Y, Diz DI, Barnes KL. The renin-angiotensin system: Physiological actions in the central nervous system. In: Zanchetti A, Tarazi RC, eds. Pathophysiology of Hypertension. Handbook of Hypertension, vol 8. Amsterdam: Elsevier; 1986: 431–454.

2. Cox BF, Bishop VS. Neural and hormonal mechanisms of angiotensin-dependent hypertension. Am J Physiol. . 1991; 261: H1284–H1291.[Abstract/Free Full Text]

3. Bunnemann B, Fuxe K, Ganten D. The brain renin-angiotensin system: Localization and general significance. J Cardiovasc Pharmacol. . 1992; 19 (suppl 6): S51–S62.

4. Reid IA. Interactions between Ang II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. . 1992; 262: E763–E778.[Abstract/Free Full Text]

5. Steckelings U, Lebrun C, Qadri F, Veltmar A, Unger T. Role of brain angiotensin in cardiovascular regulation. J Cardiovasc Pharmacol. . 1992; 19 (suppl 6): S72–S79.

6. Printz MP, Ganten D, Unger T, Phillips M. Minireview: the brain renin-angiotensin system. In: Ganten D, Printz MP, Phillips MI, Schoelkens BA, eds. Experimental Brain Research, Suppl 4. Berlin: Springer; 1982: 3–52.

7. Dzau VJ, Ingelfinger J, Pratt RE, Ellison KE. Identification of renin and angiotensinogen messenger RNA sequences in mouse and rat brain. Hypertension. . 1986; 8: 544–548.[Abstract/Free Full Text]

8. Bottari SP, Gasparo M, Steckelings M, Levens NR. Angiotensin II subtypes: characterization, signalling mechanisms, and possible physiological implications. In: Ganong WF, Martini L, eds. Frontiers in Neuroendocrinology, vol 14. New York: Raven; 1993: 123–171.

9. Brooks VL. Interactions between angiotensin II and sympathetic nervous system in long-term control of blood pressure. Clin Exp Pharmacol Physiol. . 1997; 24: 83–90.[Medline] [Order article via Infotrieve]

10. Salgado HC, Krieger EM. Mechanical and renin-angiotensin system components in acute aortic coarctation hypertension. Hypertension. . 1986; 8 (suppl I): I-133–I-136.

11. Michelini LC, Oliveira M, Santos M. Baroreceptor reflex control of heart rate during development of coarctation hypertension. Hypertension. . 1992; 19 (suppl II): II-159–II-163.

12. Santos CM, Pontieri V, Leomil Neto M, Michelini LC. Losartan improves baroreflex control of heart rate of coarcted hypertensive rats. Am J Physiol. . 1995; 269: H812–H818.[Abstract/Free Full Text]

13. Santos CM, Moreira ED, Krieger EM, Michelini LC. Chronic AT1 receptor blockade alters aortic nerve activity in hypertension. Hypertension. . 1998; 31: 973–977.[Abstract/Free Full Text]

14. Michelini LC, Krieger EM. Aortic caliber changes during the development of hypertension in freely moving rats. Am J Physiol. . 1986; 250: H667–H671.

15. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell’Orto S, Piccaluga E, Turiel M, Baselli G, Cerutti S, Maliani A. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dogs. Circ Res. . 1986; 59: 178–193.[Abstract/Free Full Text]

16. Heart rate variability. Standards of measurement, physiological interpretation and clinical use: Task Force of the European Society of Cardiology and North American Society of Pacing and Electrophysiology. Circulation. . 1996; 93: 1043–1065.[Free Full Text]

17. Moreira ED, Ida F, Krieger EM. Extent of rapid baroreceptor resetting during first hours of hypertension. Am J Physiol. . 1989; 257: H711–H716.[Abstract/Free Full Text]

18. Irigoyen MCC, Krieger EM. Baroreflex control of sympathetic activity in experimental hypertension. Braz J Med Biol Res. . 1998; 31: 1213–1220.[Medline] [Order article via Infotrieve]

19. Pontieri V, Venezuela MK, Scavove C, Michelini LC. Role of endogenous nitric oxide in the nucleus tractus solitarii on baroreflex control of heart rate in spontaneously hypertensive rats. J Hypertens. . 1998; 16: 1993–1999.[Medline] [Order article via Infotrieve]

20. Korner PI. Central and peripheral resetting of the baroreceptor system. Clin Exp Pharmacol Physiol. . 1975; 2: 171–178.[Medline] [Order article via Infotrieve]

21. Guo GB, Abboud FM. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol. . 1984; 246: H80–H89.[Abstract/Free Full Text]

22. Berecek KH, Kirk KA, Nagahama S, Oparil S. Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. AmJ Physiol. . 1987; 252: H796–H806.[Abstract/Free Full Text]

23. Moreira ED, Oliveira M, Krieger EM. Impaired baroreflex control of heart rate in high-renin renal hypertension. J Hypertens. . 1988; 6: 619–625.[Medline] [Order article via Infotrieve]

24. Moreira ED, Ida F, Oliveira VLL, Krieger EM. Early depression of baroreceptor sensitivity during onset of hypertension. Hypertension. . 1992; 19 (suppl II): II-198–II-201.

25. Lee WB, Ismay MJ, Lumbers ER. Mechanisms by which angiotensin II affects the heart rate of conscious sheep. Circ Res. . 1980; 47: 286–292.[Abstract/Free Full Text]

26. Goldstein DS. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. Am J Cardiol. . 1981; 48: 1147–1154.[Medline] [Order article via Infotrieve]

27. Luft FC, Wilcox CS, Unger T. Angiotensin-induced hypertension in the rat: sympathetic nerve activity and prostaglandins. Hypertension. . 1989; 14: 396–403.[Abstract/Free Full Text]

28. Kline RL, Chow KY, Mercer PF. Does enhanced sympathetic tone contribute to angiotensin II hypertension in rats? Eur J Pharmacol. . 1990; 184: 109–118.[Medline] [Order article via Infotrieve]

29. Carroll RG, Lohmeier TE, Brown AJ. Chronic angiotensin II infusion decreases renal norepinephrine overflow in conscious dogs. Hypertension. . 1984; 6: 675–681.[Abstract/Free Full Text]

30. Irigoyen MC, Moreira RD, Moreira ED, Krieger EM. High-renin renal hypertension depresses the baroreflex control of heart rate and sympathetic activity. In: Kunos G, Ciriello J, eds. Central Neural Mechanisms in Cardiovascular Regulation. Boston: Birkhäuser; 1991: 254–264.

31. Julius S, Nesbitt S. Sympathetic overactivity in hypertension: a moving target. Am J Hypertens. . 1996; 9: 113–120.

32. Eckberg DL. Sympathovagal balance: a critical appraisal. Circulation. . 1997; 96: 3224–3232.[Free Full Text]

33. Krieger EM, Salgado HC, Michelini LC. Resetting of baroreceptors. Int Rev Physiol. . 1982; 26: 119–146.[Medline] [Order article via Infotrieve]

34. Parati G, Saul JP, Di Renzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation: a critical appraisal. Hypertension. . 1995; 25: 1276–1286.[Abstract/Free Full Text]

35. Lumbers ER, McCloskey DI, Potter EK. Inhibition by angiotensin II of baroreceptor-evoked activity in vagal efferent nerves in the dog. J Physiol (Lond). . 1979; 294: 69–80.[Abstract/Free Full Text]

36. Lenkei Z, Palkovits M, Corvol P, Llorens-Cortès C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol. . 1997; 18: 383–439.[Medline] [Order article via Infotrieve]

37. Michelini LC, Bonagamba LGH. Angiotensin II as a modulator of baroreceptor reflexes in the brainstem of conscious rats. Hypertension. . 1990; 15 (suppl I): I-45–I-50.

38. Collister JP, Hornfeldt BJ, Osborn JW. Hypotensive response to losartan in normal rats. Role of Ang II and the area postrema. Hypertension. . 1996; 27: 598–606.[Abstract/Free Full Text]

39. Barnes KL, McQueeney AJ, Ferrario CM. Receptor subtype that mediates the neuronal effects of angiotensin II in the rat dorsal medulla. Brain Res Bull. . 1993; 31: 195–200.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
HypertensionHome page
A. C. da Costa-Goncalves, J. Tank, R. Plehm, A. Diedrich, M. Todiras, M. Gollasch, A. Heuser, M. Wellner, M. Bader, J. Jordan, et al.
Role of the Multidomain Protein Spinophilin in Blood Pressure and Cardiac Function Regulation
Hypertension, October 1, 2008; 52(4): 702 - 707.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Brili, D. Tousoulis, C. Antoniades, C. Vasiliadou, M. Karali, N. Papageorgiou, N. Ioakeimidis, K. Marinou, E. Stefanadi, and C. Stefanadis
Effects of Ramipril on Endothelial Function and the Expression of Proinflammatory Cytokines and Adhesion Molecules in Young Normotensive Subjects With Successfully Repaired Coarctation of Aorta A Randomized Cross-Over Study.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 742 - 749.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. V. C. Felix and L. C. Michelini
Training-Induced Pressure Fall in Spontaneously Hypertensive Rats Is Associated With Reduced Angiotensinogen mRNA Expression Within the Nucleus Tractus Solitarii
Hypertension, October 1, 2007; 50(4): 780 - 785.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Nishikino, T. Matsunaga, K. Yasuda, T. Adachi, T. Moritani, G. Tsujimoto, K. Tsuda, and N. Aoki
Genetic Variation in the Renin-Angiotensin System and Autonomic Nervous System Function in Young Healthy Japanese Subjects
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4676 - 4681.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
Y. Chen, L. F. Joaquim, V. M. Farah, R. B. Wichi, R. Fazan Jr., H. C. Salgado, and M. Morris
Cardiovascular autonomic control in mice lacking angiotensin AT1a receptors
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R1071 - R1077.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. T. Sangaleti, A. Crescenzi, and L. C. Michelini
Endogenous Angiotensin and Pressure Modulate Brain Angiotensinogen and AT1A mRNA Expression
Hypertension, February 1, 2004; 43(2): 317 - 323.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. C. Michelini, M. C. Marcelo, J. Amico, and M. Morris
Oxytocinergic regulation of cardiovascular function: studies in oxytocin-deficient mice
Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2269 - H2276.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bezerra, S. M.M.S.
Right arrow Articles by Michelini, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bezerra, S. M.M.S.
Right arrow Articles by Michelini, L. C.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow ACE/Angiotension receptors
Right arrow Other hypertension
Right arrow Hypertension - basic studies
Right arrow Autonomic, reflex, and neurohumoral control of circulation